Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
BIO-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmory Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Sep 30, 2020: Can-Fite selected to deliver late-breaking oral presentation on modenoson’s treatment of SH at American Association for the Study of Liver Diseases Conference
Aug 31, 2020: FDA clears Can-Fite to commence phase II COVID-19 study
Aug 25, 2020: Can-Fite receives notification of patent grant from European Patent Office for modenoson in the treatment of SH
Jul 27, 2020: Can-Fite submits Investigatiol New Drug Application to U.S. FDA for COVID-19 phase II Study
Jul 20, 2020: Can-Fite completes development of an assay to identify clinically active canbis derived compounds
Jul 15, 2020: Can-Fite completes phase II COVID-19 protocol based on FDA guidance, plans to file IND shortly
Jun 30, 2020: Can-Fite announces fil data alysis from phase II SH study: Highly significant and sustained reduction in liver fat volume throughout study period
Jun 09, 2020: Following Pre-IND guidance from FDA Can-Fite to Advance Piclidenoson into phase II COVID-19 trial in the U.S.
Jun 08, 2020: Can-Fite participating in BIO Digital Intertiol Convention and One-on-One partnering meetings on June 8-12, 2020
Jun 05, 2020: Can-Fite plans Phase III liver cancer trial of modenoson in Europe
May 21, 2020: Can-Fite receives notice of allowance for modenoson Patent in the Treatment of SH & FLD from U.S. Patent and Trademark Office
May 18, 2020: Can-Fite reports additiol findings from successful phase II SH Study: 25 mg Dose of modenoson significantly reduced liver fat and fibrosis
May 15, 2020: Can-Fite announces pre-IND submission to U.S. FDA for Piclidenoson in the treatment of covid-19 infected patients with moderate-to-severe symptoms
Apr 14, 2020: Can Fite to conduct investor call to review positive phase II SH data
Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by BioIntervene Inc, H2 2020
Pipeline by Can-Fite BioPharma Ltd, H2 2020
Pipeline by Future Medicine Co Ltd, H2 2020
Pipeline by Palo BioFarma SL, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020